Coronary Artery Restenosis in Women by History of Preeclampsia
暂无分享,去创建一个
M. Pihlsgård | G. Sarno | A. Fraser | J. Rich-Edwards | S. Timpka | A. Lin | Moa Pehrson | Isabel Gonҫalves
[1] J. Ray,et al. Maternal cardiovascular disease after twin pregnancies complicated by hypertensive disorders of pregnancy: a population-based cohort study , 2021, Canadian Medical Association Journal.
[2] P. Teirstein,et al. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. , 2020, Journal of the American College of Cardiology.
[3] J. Snowden,et al. Multi-Fetal Pregnancy, Preeclampsia, and Long-Term Cardiovascular Disease , 2020, Hypertension.
[4] P. Serruys,et al. Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. , 2020, Journal of the American College of Cardiology.
[5] J. Casas,et al. Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study. , 2019, Circulation.
[6] G. Burton,et al. Pre-eclampsia: pathophysiology and clinical implications , 2019, BMJ.
[7] C. Ballantyne,et al. The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines , 2019, Current Cardiovascular Risk Reports.
[8] S. Karumanchi,et al. Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .
[9] Volkmar Falk,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.
[10] L. Buckley,et al. Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. , 2018, Journal of the American College of Cardiology.
[11] Thomas M Maddox,et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, , 2017, Journal of the American College of Cardiology.
[12] B. Merkely,et al. Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent , 2017, Disease markers.
[13] W. Qiu,et al. Gender Differences in Outcomes and Predictors of All-Cause Mortality After Percutaneous Coronary Intervention (Data from United Kingdom and Sweden). , 2017, The American journal of cardiology.
[14] Bernardo Cortese,et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. , 2016, Journal of thoracic disease.
[15] A. Avogaro,et al. Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. , 2016, Circulation research.
[16] A. Jacobs,et al. Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age , 2016, Circulation. Cardiovascular quality and outcomes.
[17] G. Booth,et al. Prognosis after maternal placental events and revascularization: PAMPER study. , 2016, American journal of obstetrics and gynecology.
[18] S. Salimi,et al. Vascular endothelial growth factor (VEGF)‐634G/C polymorphism was associated with severe pre‐eclampsia and lower serum VEGF level , 2015, The journal of obstetrics and gynaecology research.
[19] B. Cohn,et al. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. , 2015, Circulation.
[20] M. Aronovitz,et al. Exposure to Experimental Preeclampsia in Mice Enhances the Vascular Response to Future Injury , 2015, Hypertension.
[21] Ruei-Zeng Lin,et al. Decreased Level of Cord Blood Circulating Endothelial Colony–Forming Cells in Preeclampsia , 2014, Hypertension.
[22] A. Lovering,et al. Decreased endothelial progenitor cells in preeclampsia and consequences for developmental programming. , 2014, Hypertension.
[23] I. Sargent,et al. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? , 2014, Placenta.
[24] E. Omerovic,et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2012, European heart journal.
[25] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[26] P. Damman,et al. 1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. , 2011, JACC. Cardiovascular interventions.
[27] C. Hubel,et al. Maternal Circulating CD34+VEGFR-2+ and CD133+VEGFR-2 + Progenitor Cells Increase During Normal Pregnancy but Are Reduced in Women With Preeclampsia , 2010, Reproductive Sciences.
[28] Ole Fröbert,et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). , 2009, Journal of the American College of Cardiology.
[29] K. Lim,et al. Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.
[30] B. Källén,et al. A Quality Study of a Medical Birth Registry , 1990, Scandinavian journal of social medicine.